ATOS - Company ID 0001488039
The table below shows ATOSSA THERAPEUTICS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $4.78M | $5.37M | $5.50M | $4.16M | $3.41M | $3.55M |
| SG&A |
ATOSSA THERAPEUTICS, INC. reported annual revenue of $1.76K for fiscal year 2015. That is down 95.6% from $40.14K in fiscal 2014. Over the 5 fiscal years shown, annual revenue grew from $1.50K (FY 2011) to $1.76K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.09M |
| $3.88M |
| $3.54M |
| $3.26M |
| $2.97M |
| $3.55M |
| Operating income | -$9.87M | -$9.25M | -$9.04M | -$7.41M | -$6.38M | -$7.11M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$9.59M | -$8.69M | -$8.42M | -$6.72M | -$7.23M | -$6.05M |
| EPS (diluted) | -$1.11 | -$0.07 | -$0.07 | -$0.78 | -$0.06 | -$0.05 |